Piobot 7.5 Tablet contains Pioglitazone 7.5 mg, an effective oral antidiabetic agent from the thiazolidinedione class that enhances insulin sensitivity and improves glucose utilization in patients with type 2 diabetes mellitus.
This lower-dose Pioglitazone formulation is ideal for patients requiring gentle glycemic control or those being introduced to therapy alongside Metformin or Sulfonylureas. It helps reduce fasting and post-meal blood-glucose levels and supports long-term metabolic balance.
Piobot 7.5 Tablet belongs to the antidiabetic and endocrinology segment, offering consistent efficacy with excellent tolerability. It is recommended for PCD pharma franchise partners, third-party manufacturers, and exporters seeking a trusted insulin-sensitizing agent for their portfolio.
With the increasing burden of type 2 diabetes in India and worldwide, Pioglitazone 7.5 mg offers a profitable business opportunity in the growing antidiabetic market.
Common side effects may include mild weight gain, swelling, headache, and fatigue. In rare cases, it can cause fluid retention, heart failure, or liver-related issues. Patients should report any unusual symptoms like shortness of breath, sudden weight gain, or jaundice to their healthcare provider.
Piobot 7.5 Tablet is indicated for the management of type 2 diabetes mellitus, particularly in adults whose blood sugar levels are inadequately controlled through diet and exercise alone. It may be used alone or in combination with other oral antidiabetic agents to improve glycemic control.
Take Piobot 7.5 Tablet exactly as prescribed, with or without food, at a consistent time each day. Regular monitoring of blood glucose, liver function, and weight is important during therapy. Use with caution if you have a history of heart disease, liver problems, or bladder cancer.
Store Piobot 30 Tablet in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep the medication out of reach of children.